[Articles] Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group

Both eBEACOPP variants met the co-primary efficacy endpoints. Particularly, the BrECADD regimen was associated with a more favourable toxicity profile and was, therefore, selected to challenge standard eBEACOPP for the treatment of advanced classical Hodgkin's lymphoma in the phase 3 HD21 study by the German Hodgkin Study Group (NCT02661503), which aims to further reduce treatment-related morbidity.

Source: The Lancet Oncology - November 10, 2017 Category: Cancer & Oncology Authors: Dennis A Eichenauer, Annette Pl ütschow, Stefanie Kreissl, Martin Sökler, Johannes C Hellmuth, Julia Meissner, Stephan Mathas, Max S Topp, Karolin Behringer, Wolfram Klapper, Georg Kuhnert, Markus Dietlein, Carsten Kobe, Michael Fuchs, Volker Diehl, And Tags: Articles Source Type: research